Published in Nature Communications · View the paper (DOI)
A gene therapy trial has shown significant improvements in children with primary AADC deficiency, a devastating genetic disorder characterized by severe motor disability and developmental delay. The treatment targets neurons that produce dopamine, resulting in improved motor function, better mood, and longer sleep.
Coverage from 2 institutions